677 related articles for article (PubMed ID: 32603815)
1. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases.
Yu W; Wu Z
Adv Drug Deliv Rev; 2021 Jan; 168():181-195. PubMed ID: 32603815
[TBL] [Abstract][Full Text] [Related]
2. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
Wan T; Ping Y
Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
Li C; Brant E; Budak H; Zhang B
J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
[TBL] [Abstract][Full Text] [Related]
4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
5. Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease.
Hung SSC; McCaughey T; Swann O; Pébay A; Hewitt AW
Prog Retin Eye Res; 2016 Jul; 53():1-20. PubMed ID: 27181583
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
7. Viral Delivery of Compact CRISPR-Cas12f for Gene Editing Applications.
Sharrar A; Meacham Z; Staples-Ager J; Arake de Tacca L; Rabuka D; Collingwood T; Schelle M
CRISPR J; 2024 Jun; 7(3):150-155. PubMed ID: 38695159
[TBL] [Abstract][Full Text] [Related]
8. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
[TBL] [Abstract][Full Text] [Related]
9. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.
Wang D; Zhang F; Gao G
Cell; 2020 Apr; 181(1):136-150. PubMed ID: 32243786
[TBL] [Abstract][Full Text] [Related]
11. CRISPR Systems Suitable for Single AAV Vector Delivery.
Stevanovic M; Piotter E; McClements ME; MacLaren RE
Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
[TBL] [Abstract][Full Text] [Related]
12. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
Shalaby K; Aouida M; El-Agnaf O
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
[TBL] [Abstract][Full Text] [Related]
13. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.
Taha EA; Lee J; Hotta A
J Control Release; 2022 Feb; 342():345-361. PubMed ID: 35026352
[TBL] [Abstract][Full Text] [Related]
14. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
Yu W; Wu Z
Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
[TBL] [Abstract][Full Text] [Related]
15. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Hung SS; Chrysostomou V; Li F; Lim JK; Wang JH; Powell JE; Tu L; Daniszewski M; Lo C; Wong RC; Crowston JG; Pébay A; King AE; Bui BV; Liu GS; Hewitt AW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3470-6. PubMed ID: 27367513
[TBL] [Abstract][Full Text] [Related]
16. CRISPR applications in ophthalmologic genome surgery.
Cabral T; DiCarlo JE; Justus S; Sengillo JD; Xu Y; Tsang SH
Curr Opin Ophthalmol; 2017 May; 28(3):252-259. PubMed ID: 28141764
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic applications of CRISPR/Cas9 gene editing technology for the treatment of ocular diseases.
Sundaresan Y; Yacoub S; Kodati B; Amankwa CE; Raola A; Zode G
FEBS J; 2023 Nov; 290(22):5248-5269. PubMed ID: 36877952
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
19. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas gene therapy.
Zhang B
J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
